seleon develops and produces complex medical devices on behalf of customers and ensures their approval.
Since 2022, baseclick is provider in custom synthesis of mRNA for research and pre-clinical applications. Our team of experts transforms your mRNA design ranging from research tool to mRNA product development.
baseclick enables life science researchers to create better solutions in diagnostics, therapeutics and vaccines development through a proprietary click chemistry.
We are on a mission to change the way therapeutics and vaccines are developed and manufactured. By focusing on targeted delivery agents instead of lipid nanoparticles (LNPs), we leverage the significant benefits of our modified nucleic acid building blocks to pioneer novel therapies and compounds. Our goal is to develop treatments for disease patients and improve the lives of millions of people around the world.
Click technology holds the promise to revolutionize the mRNA Technology in drug development for cancer treatment, vaccine discovery and enables tailored manufactured mRNA with superior quality.
baseclick supplies diverse types of mRNA
– High quality products and services at competitive prices
– Custom tailored support to meet specific applications
– Wide variety of modification
– Affordable custom synthesis up to 10 mg scales of mRNA
An uridine derivate for replacement of uridine in mRNA-based therapies and vaccines. Modified mRNA shows prolonged expression and confers similar low immunogenicity compared to the other uridine derivates such a pseudo-uridine and methyl-pseudo-uridine.
Tri-GalNAc-DBCO enables the possibility to click label an azide modified nucleic acid molecule with an Tri-GalNAc by strain-promoted Alkyne-Azide cycloaddition (SPAAC). The Tri-GalNAc structure is recognized by the cellular surface protein asialoglycoprotein receptor (ASGPR) and can be used for targeted delivery of biomolecules such as siRNA, ASOs, mRNA etc. into ASGPR expressing cells for example to liver cells.
Azido-PEG4-Trimannose enables the possibility to click label an Alkyne or DBCO modified nucleic acids with an 3,6-di-O-(α-D-mannopyranosyl)-α-D-mannopyranoside moity by CuAAC. The Trimannose structure is recognized by the mannose receptor and leads to transportation into the cell by internalized receptor mediated endocytosis. Therefore, this molecule offers a possibility for target delivery of biomolecules to the cell.
Tri-GalNAc-DBCO enables the possibility to click label an azide modified nucleic acid molecule with an Tri-GalNAc by strain-promoted Alkyne-Azide cycloaddition (SPAAC). The Tri-GalNAc structure is recognized by the cellular surface protein asialoglycoprotein receptor (ASGPR) and can be used for targeted delivery of biomolecules such as siRNA, ASOs, mRNA etc. into ASGPR expressing cells for example to liver cells.
You are searching for individual oligonucleotides? baseclick is offering special DNAs, RNAs and even LNAs for your specific application. We are glad to provide you with a wide range of special modifications.
The identification of pseudo- and N1-methylpseudo-uridine (Ψ and mΨ, respectively) as immunosilent uridine analogues has propelled the development of mRNA-based vaccines and therapeutics. Here, we have characterised another uridine analogue, 5-ethynyluridine (EU), which has an ethynyl moiety. We show that this uridine analogue does not cause immune activation in human macrophages, as it does not induce interleukin-6 secretion or expression of the inflammatory and antiviral genes MX1, PKR, and TAP2. Moreover, EU allows for prolonged expression, as shown with mRNA coding for yellow fluorescent protein (YFP). Side-by-side comparisons of EU with unmodified, Ψ, and mΨ revealed that EU-modified mRNA is expressed at lower levels, but confers similar stability and low immunogenicity to the other uridine analogues. Furthermore, structure analysis of modified mRNAs suggests that the observed phenotype is largely independent of RNA folding. Thus, EU is a potential candidate for RNA-based vaccines and therapeutics.
Recent studies of severe acute inflammatory lung disease including COVID-19 identify macrophages to drive pulmonary hyperinflammation and long-term damage such as fibrosis. Here, we report on the development of a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), as a therapeutic means against pulmonary hyperinflammation and fibrosis. MicroRNA-21 is among the strongest upregulated microRNAs in human COVID-19 and in mice with acute inflammatory lung damage, and it is the strongest expressed microRNA in pulmonary macrophages. Chemical linkage of a microRNA-21 inhibitor to trimannose achieves rapid and specific delivery to macrophages upon inhalation in mice. RCS-21 reverses pathological activation of macrophages and prevents pulmonary dysfunction and fibrosis after acute lung damage in mice. In human lung tissue infected with SARS-CoV-2 ex vivo, RCS-21 effectively prevents the exaggerated inflammatory response. Our data imply trimannose-coupling for effective and selective delivery of inhaled oligonucleotides to pulmonary macrophages and report on a first mannose-coupled candidate therapeutic for COVID-19.
PL BioScience creates xeno-free cell culture supplements for cell research and therapy development through an ethical and safe production process. Our ELAREM™ HPL platform is crafted from pooled, upcycled transfusion-approved platelet units, providing optimal conditions for cell expansion.
At PL BioScience, we are dedicated to bridging the gap between research and clinical applications. Our mission is to advance regenerative medicine with our animal-free cell culture tools, producing human Platelet Lysates that have the potential to elevate both stem cell research and therapy to the next level.
MetisMotion manufactures modular actuator systems based on the patented naXture technology. Developed and designed according to a unique model from nature: the human muscle.
We learn from the best! With our naXture technology, we combine the most effective features from existing drive technologies with the growing demands for efficiency and sustainability, and translate them into solutions and systems tailored to specific customers.
Resusitec develops, produces and markets cutting-edge technology for emergency and intensive care medicine to ensure safe patient care.
eleva is a clinical-stage biopharmaceutical company developing novel therapies and unlocking difficult-to-produce biologics based on a transformative manufacturing platform.
We harness the outstanding capabilities of our moss-based platform to create candidates no one else can and advance them into clinical development.
The ability to manufacture biologics effectively and at scale has become a crucial success factor in the pharmaceutical industry – and its importance will only continue to grow. Novel expression strategies can provide access to previously uncharted biologics, improve essential drug properties, and deliver not just “more,” but a superior product from the outset.
eleva is uniquely positioned in these markets with its proprietary moss-based manufacturing platform, which has the potential to unlock difficult-to-produce biological therapies.
We substantiate this claim by independently advancing a portfolio of therapeutic candidates into clinical development and attracting partners for de novo projects. Factor H (CPV-104), our recombinant version of human complement Factor H, is expected to enter clinical studies for its lead indication, C3 Glomerulopathy (C3G), in the first half of 2025. Additionally, our recombinant version of α-galactosidase aGal (RPV-001) has already demonstrated promising initial clinical data in Fabry disease.
All programs are derived from eleva’s transformative moss-based expression system, which enables lab-to-GMP-scale manufacturing of challenging proteins with refined and optimized product characteristics. We believe there are numerous opportunities in our industry that would benefit from a synergistic expression strategy and platform integrated from the start and throughout the entire product development roadmap.
xenios is a leading medtech company offering innovative solutions in extracorporeal heart and lung support. Focused on acute and long-term respiratory and cardiac assistance, Xenios enables clinicians to stabilize patients when conventional therapies are insufficient.
Schwarzer Cardiotek is a specialized medtech company focused on hemodynamic and electrophysiological measurement systems. With over 60 years of experience and 1,800+ installations worldwide, it stands for excellence in cardiovascular diagnostics and data management.
Protagen Protein Services (PPS) and GeneWerk have merged to form a premier analytical service platform for the biopharmaceutical industry. Together, they deliver cutting-edge testing solutions for both protein characterization and gene therapy – from early development through to commercialization.
Inspekto is a trailblazer in the field of autonomous machine vision, delivering high-performance, AI-driven inspection solutions for industrial manufacturing. Its technology replicates human cognitive visual inspection, enabling smarter and more flexible quality control across multiple industries.